This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Jun 20;373(9681):2088-90.

doi: 10.1016/S0140-6736(09)61029-1. Epub 2009 Jun 6.

Thiazolidinediones and clinical outcomes in type 2 diabetes

Ravi Retnakaran¹, Bernard Zinman

Affiliations

PMID: 19501899
DOI: 10.1016/S0140-6736(09)61029-1

Comment

Thiazolidinediones and clinical outcomes in type 2 diabetes

Ravi Retnakaran et al. Lancet. 2009.

. 2009 Jun 20;373(9681):2088-90.

doi: 10.1016/S0140-6736(09)61029-1. Epub 2009 Jun 6.

Authors

Ravi Retnakaran¹, Bernard Zinman

Affiliation

¹ Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, 60 Murray Street, Toronto, ON M5T 3L9, Canada.

PMID: 19501899
DOI: 10.1016/S0140-6736(09)61029-1

No abstract available

PubMed Disclaimer

Comment on

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Home PD, et al. Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6. Lancet. 2009. PMID: 19501900 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information